Granted Patent B2

US 10,138,520 · App. 14/442,439 · Granted Nov 27, 2018

Inventors: Andreas Keller (Püttlingen, DE); Cord Friedrich Stähler (Hirschberg an der Bergstraße, DE); Eckart Meese (Hütschenhausen, DE); Andreas Kappel (Glashuetten, DE); Christina Backes (Saarbrücken, DE); Petra Leidinger (Wadern, DE)

Assignee: SIEMENS AKTIENGESELLSCHAFT

C12Q1/6883C12Q1/6809G06F19/22C12Q2600/118C12Q2600/158C12Q2600/16C12Q2600/178

Abstract

Claims (61)

1. A method of treating Alzheimer's Disease in a patient in need thereof, said method comprising

administering an anti-Alzheimer's Disease therapy to the patient, wherein a blood sample from the patient exhibits an expression level value of at least one miRNA selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO 236 compared to a reference expression level value.

2. The method according to claim 1 , wherein the at least one miRNA from the sample is selected from the group consisting of SEQ ID NO 59, SEQ ID NO 65, SEQ ID NO 1, and SEQ ID NO 56.

3. The method according to claim 1 , wherein the at least one miRNA from the sample includes all seven of brain-miR-112, hsa-miR-5010-3p, hsa-miR-103a-3p, hsa-miR-107, hsa-let-7d-3p, hsa-miR-532-5p, and brain-miR-161.

4. The method according to claim 1 , wherein the at least one miRNA from the sample includes a set of 5 miRNAs selected from the group consisting of

brain-mir-112 hsa-miR-5010-3p hsa-miR-1285-5p hsa-miR-151a-3p

hsa-let-7f-5p,

hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-148b-5p

hsa-miR-144-5p,

hsa-miR-3127-3p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p

hsa-miR-144-5p,

hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-151a-3p

hsa-miR-144-5p,

hsa-miR-1285-5p brain-mir-112 hsa-miR-5010-3p hsa-miR-151a-3p

hsa-let-7a-5p,

hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-425-5p hsa-miR-148b-5p

hsa-miR-144-5p,

hsa-miR-3127-3p hsa-miR-1285-5p hsa-miR-148b-5p hsa-miR-151a-3p

hsa-miR-144-5p,

hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-425-5p hsa-miR-148b-5p

hsa-miR-144-5p,

hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p

hsa-let-7a-5p,

hsa-miR-1285-5p brain-mir-112 hsa-miR-425-5p hsa-miR-151a-3p

hsa-miR-144-5p,

hsa-miR-5001-3p hsa-miR-1285-5p brain-mir-112 hsa-miR-151a-3p

hsa-let-7f-5p,

hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-148b-5p hsa-miR-144-5p

hsa-let-7f-5p,

hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-148b-5p hsa-miR-151a-3p

hsa-miR-144-5p,

hsa-miR-5001-3p hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p

hsa-let-7f-5p,

brain-mir-431 hsa-miR-1285-5p hsa-miR-3157-3p hsa-miR-151a-3p

hsa-miR-144-5p,

hsa-miR-3127-3p hsa-miR-1285-5p brain-mir-112 hsa-miR-425-5p

hsa-miR-151a-3p,

hsa-miR-1285-5p hsa-miR-5010-3p hsa-miR-151a-3p hsa-miR-144-5p

hsa-let-7f-5p,

hsa-miR-550a- 5phsa-miR-1285-5p brain-mir-112 hsa-miR-151a-3p

hsa-let-7f-5p,

hsa-miR-1285-5p brain-mir-112 hsa-miR-148b-5p hsa-miR-151a-3p

hsa-miR-144-5p, and

hsa-miR-5001-3p brain-mir-112 hsa-miR-5010-3p hsa-miR-151a-3p

hsa-let-7f-5p.

5. The method according to claim 4 , further comprising adding the expression level values of the set of five miRNAs.

6. The method according to claim 1 , wherein the determination of the expression level value of the at least one miRNA from the sample is obtained by use of a method selected from the group consisting of a sequencing-based method, an array-based method and a PCR-based method.

7. The method according to claim 1 , wherein the expression levels values of at least 2 miRNAs in the sample are determined.

8. The method according to claim 1 , wherein the blood sample from the patient also exhibits an expression level value of at least one miRNA selected from the group consisting of hsa-miR-26b-3p, hsa-miR-26a-5p, brain-miR-161 and hsa-miR-5010-3p compared to a reference expression level value.

9. A kit for performing the method according to claim 1 , said kit comprising

means for determining in said blood sample from said patient, an expression level value of at least one miRNA selected from the group consisting of miRNAs having the sequence SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO 236.

10. The kit of claim 9 , further comprising at least one reference pattern of expression levels values for comparing with the expression level values of the at least one miRNA from said sample.

11. The method according to claim 7 , wherein the expression level values of at least 3 miRNAs in the sample are determined.

12. The method according to claim 11 , wherein the expression level values of at least 4 miRNAs in the sample are determined.

13. The method according to claim 12 , wherein the expression level values of at least 5 miRNAs in the sample are determined.

14. The method according to claim 13 , wherein the expression level values of at least 6 miRNAs in the sample are determined.

15. The method according to claim 14 , wherein the expression level values of at least 7 miRNAs in the sample are determined.

16. The method according to claim 15 , wherein the expression level values of at least 8 miRNAs in the sample are determined.

17. The method according to claim 16 , wherein the expression level values of at least 9 miRNAs in the sample are determined.

18. The method according to claim 17 , wherein the expression level values of at least 10 miRNAs in the sample are determined.

19. The method according to claim 18 , wherein the expression level values of at least 12 miRNAs in the sample are determined.

Assignments (9)

Priority Claims (1)

Continuity (1)